170 related articles for article (PubMed ID: 34166174)
1. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
Godman B; Haque M; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Allocati E; Bakar MA; Rahim SA; Sultana N; Deeba F; Halim Khan MA; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Acharya J; Sugahara T; Kwon HY; Bae S; Khuan KKP; Khan TA; Hussain S; Saleem Z; Pisana A; Wale J; Jakovljevic M
Curr Med Res Opin; 2021 Sep; 37(9):1529-1545. PubMed ID: 34166174
[TBL] [Abstract][Full Text] [Related]
2. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
Front Public Health; 2021; 9():671961. PubMed ID: 34249838
[No Abstract] [Full Text] [Related]
3. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
[TBL] [Abstract][Full Text] [Related]
4. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.
Haque M; Islam S; Kamal ZM; Akter F; Jahan I; Rahim MSA; Sultana N; Alam AM; Munzur-E-Murshid ; Halim-Khan MA; Deeba F; Bakar MA; Nahar S; Mozaffor M; Urmi UL; Saikat TR; Islam MZ; Haque M; Iqbal S; Hossain MM; Naher N; Allocati E; Godman B
Hosp Pract (1995); 2021 Oct; 49(4):266-272. PubMed ID: 33734004
[TBL] [Abstract][Full Text] [Related]
5. Insulin prices, availability and affordability in 13 low-income and middle-income countries.
Ewen M; Joosse HJ; Beran D; Laing R
BMJ Glob Health; 2019; 4(3):e001410. PubMed ID: 31263585
[TBL] [Abstract][Full Text] [Related]
6. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
[No Abstract] [Full Text] [Related]
7. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications.
Tubic B; Marković-Peković V; Jungić S; Allocati E; Godman B
Med Access Point Care; 2021; 5():23992026211027692. PubMed ID: 36204505
[TBL] [Abstract][Full Text] [Related]
8. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
9. Production costs and potential prices for biosimilars of human insulin and insulin analogues.
Gotham D; Barber MJ; Hill A
BMJ Glob Health; 2018; 3(5):e000850. PubMed ID: 30271626
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar Insulin and Costs: What Can We Expect?
Heinemann L
J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
[TBL] [Abstract][Full Text] [Related]
12. [Insulin therapy-new insulin analogues].
Ehren M; Klein HH
Internist (Berl); 2019 Sep; 60(9):887-894. PubMed ID: 31396651
[TBL] [Abstract][Full Text] [Related]
13. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
[TBL] [Abstract][Full Text] [Related]
14. Insulin biobetters and biosimilars in clinical practice.
Home P
J R Coll Physicians Edinb; 2023 Jun; 53(2):147-155. PubMed ID: 37198930
[TBL] [Abstract][Full Text] [Related]
15. Innovative insulins--where do analogues fit?
Phillips LK; Phillips PJ
Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.
Lee TY; Kuo S; Yang CY; Ou HT
Br J Clin Pharmacol; 2020 May; 86(5):852-860. PubMed ID: 31782975
[TBL] [Abstract][Full Text] [Related]
17. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.
Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Plank J; Pieber TR; Gerlach FM
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD012161. PubMed ID: 27362975
[TBL] [Abstract][Full Text] [Related]
18. The biosimilar insulin landscape: current developments.
Lavalle-González FJ; Khatami H
Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
[TBL] [Abstract][Full Text] [Related]
19. Insulin biosimilars: the impact on rapid-acting analogue-based therapy.
Franzè S; Cilurzo F; Minghetti P
BioDrugs; 2015 Apr; 29(2):113-21. PubMed ID: 25773234
[TBL] [Abstract][Full Text] [Related]
20. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.
Pedersen-Bjergaard U; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L
Lancet Diabetes Endocrinol; 2014 Jul; 2(7):553-61. PubMed ID: 24794703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
